Viewing Study NCT00195403


Ignite Creation Date: 2025-12-24 @ 7:40 PM
Ignite Modification Date: 2025-12-25 @ 5:20 PM
Study NCT ID: NCT00195403
Status: COMPLETED
Last Update Posted: 2013-08-15
First Post: 2005-09-12
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA
Sponsor: Pfizer
Organization:

Study Overview

Official Title: A Drug Use Investigation of Enbrel for Post-Marketing Surveillance
Status: COMPLETED
Status Verified Date: 2013-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objective of this investigation is to identify the following problems and questions with respect to the safety and efficacy of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s regulation.

1. Unknown adverse reactions, especially serious adverse reactions
2. Incidences of adverse reactions under routine drug uses
3. Factors that may affect the safety of the drug
4. Factors that may affect the efficacy of the drug

This investigation spanned 3 different studies, 0881A-101575 (alias B1801105) NCT00195403, 0881A-102018 (alias B1801112) NCT00195416 and 0881A-102212 (alias B1801113). All studies have been combined into this record.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: